Lucid Diagnostics Inc. (LUCD): Business Model Canvas [Apr-2026 Updated]

You're looking for the real mechanics behind Lucid Diagnostics' plan to bring non-invasive esophageal precancer screening to market, and honestly, that's the right place to start. From my seat, having analyzed healthcare firms for years, their Business Model Canvas shows a classic high-potential med-tech play: proprietary tech (EsoGuard/EsoCheck) aiming to replace invasive procedures, supported by a key relationship with PAVmed Inc. and early health system adoption. The near-term reality, reflected in their Q3 2025 results, is $1.2 million in test revenue while burning cash, making their Key Activity of securing Medicare reimbursement the single biggest driver for future value, sitting atop $47.3 million in cash as of September 30, 2025. See the full nine-block breakdown below to map out their path from clinical validation to broad payor coverage.

Lucid Diagnostics Inc. (LUCD) - Canvas Business Model: Key Partnerships

You're looking at how Lucid Diagnostics Inc. (LUCD) structures its external relationships to drive the commercialization of EsoGuard. It's not just about the test; it's about the network that gets it into the hands of at-risk patients. Here's the breakdown of the key players supporting their model as of late 2025.

PAVmed Inc. (Parent company and key financial supporter)

Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc. (Nasdaq: PAVM). This relationship is foundational, providing both corporate structure and critical financial backing. For instance, Lucid ended the third quarter of 2025 with cash and cash equivalents of $47.3 million, a position bolstered by financing activities, including a public offering netting approximately $27.0 million in Q3 2025, extending the runway through 2026. PAVmed Inc. continues to evaluate opportunities to leverage its shared services model across its diverse portfolio.

Major U.S. health systems (e.g., Hoag) for testing program rollout

Securing adoption within established healthcare delivery networks is crucial for volume. Lucid Diagnostics launched a comprehensive EsoGuard esophageal precancer testing program in partnership with Hoag, a nationally-recognized regional healthcare delivery network, in June 2025. This collaboration integrates EsoGuard testing across Hoag's digestive health, primary care, and concierge medicine programs. The expectation is that this Hoag collaboration will serve as a model for securing similar partnerships with other leading health systems.

National Institutes of Health (NIH) investigators for expanded indication studies

Clinical validation and expanding the addressable patient population rely heavily on academic partnerships. A consortium of academic medical centers, led by principal investigators from Case Western Reserve University (CWRU) and University Hospitals (UH), secured an $8 million NIH R01 grant in February 2025. This grant supports a five-year clinical study to evaluate EsoGuard in at-risk individuals who do not have symptomatic GERD, targeting an expanded indication. Furthermore, ongoing NIH studies are part of the strategy to expand the total addressable market, which Lucid anticipates could reach 50 million patients upon achieving Medicare coverage.

Commercial payors like Highmark Blue Cross Blue Shield for coverage precedent

Reimbursement is the gatekeeper for widespread commercial success. Lucid Diagnostics announced that Highmark Blue Cross Blue Shield, an independent Blue Cross Blue Shield Association licensee, issued a positive coverage policy for EsoGuard in New York state, effective May 26, 2025. This decision is viewed as a landmark event intended to serve as a precedent for driving positive coverage decisions from other commercial insurers.

Concierge medicine practices and self-insured employers for cash-pay volume

While pursuing insurance coverage, Lucid has actively focused on guaranteed revenue channels. The company continues to expand its cash-pay program focused on concierge medicine practices and direct contracting with self-insured employers. As an indicator of traction in this segment, the fourth quarter of 2024 saw the new sales channel generate over 20 new cash-pay concierge medicine contracts.

Here's a quick look at the operational output tied to these commercial efforts through the first three quarters of 2025:

Metric	Q1 2025 (Ended Mar 31)	Q2 2025 (Ended Jun 30)	Q3 2025 (Ended Sep 30)
EsoGuard Revenue	$0.8 million	$1.2 million	$1.2 million
EsoGuard Tests Processed	3,034 tests	2,756 tests	2,841 tests
Proforma Cash Position (Period End)	Over $40 million	Over $30 million	Over $47 million

The Medicare Contractor Advisory Committee (CAC) meeting in September 2025, where medical experts unanimously supported Medicare coverage for EsoGuard, represents a key step toward unlocking the broader payer segment. If onboarding takes 14+ days, churn risk rises, which is why these direct partnerships are so important right now.

Finance: draft 13-week cash view by Friday.

Lucid Diagnostics Inc. (LUCD) - Canvas Business Model: Key Activities

You're looking at the core engine of Lucid Diagnostics Inc. (LUCD) as of late 2025-the activities they must execute day-in and day-out to turn their diagnostic technology into a viable business. It's a heavy lift, balancing commercial rollout with the critical, long-term goal of securing broad payer coverage.

Commercialization and sales of EsoGuard® and EsoCheck®

The sales engine is focused on driving test volume through various channels, including traditional claims, direct contracting, and cash-pay programs. You can see the quarterly progression in the test volume and the resulting revenue recognized.

Metric	Q1 2025	Q2 2025	Q3 2025
EsoGuard Revenue	$0.8 million	$1.2 million	$1.2 million
EsoGuard Tests Processed	3,034	2,756	2,841

The revenue for the last twelve months, ending September 30, 2025, stood at $4.40 million. For context, the annual revenue in 2024 was $4.35 million.

Key commercialization achievements include:

• Secured first positive commercial insurance coverage policy from Highmark Blue Cross Blue Shield.
• Executed over 20 cash-pay concierge medicine contracts in the first few weeks of 2025.
• Nearly 40,000 patients have been referred for EsoGuard testing to date (as of July 2025).

Securing Medicare and private insurance reimbursement (MolDX LCD process)

This is arguably the most important activity right now, as Medicare coverage unlocks the largest potential revenue stream. The MolDX Local Coverage Determination (LCD) reconsideration process has reached a critical juncture.

The MolDX Contractor Advisory Committee (CAC) meeting took place on September 4, 2025, to review LCD L39256. Following this meeting, medical experts reached a unanimous expert consensus supporting Medicare coverage for EsoGuard.

The company has been actively managing its capital structure to sustain operations through this final stage. Here's a look at the cash position:

Date	Cash and Cash Equivalents (Reported)	Proforma Cash (Reported)
December 31, 2024	$22.4 million	N/A
June 30, 2025	N/A	Over $30 million
September 30, 2025	$47.3 million	$47.3 million

The Q3 2025 financing activity involved a public offering that netted approximately $27.0 million in proceeds, extending the financial runway through 2026 and past upcoming reimbursement milestones.

Clinical evidence generation and publication for test validation

The foundation for reimbursement hinges on strong clinical data. The company is focused on leveraging existing data and planning further studies.

Specific data points supporting clinical utility include:

• A clinical utility study showed that triaging with a noninvasive EsoGuard test resulted in a 2.4-fold increased positive yield of invasive endoscopy.
• In 2024, an updated American College of Gastroenterology (ACG) guideline and an American Gastroenterological Association (AGA) clinical practice update endorsed non-endoscopic biomarker tests as an acceptable alternative to endoscopy.

Lucid Diagnostics Inc. is planning several EsoGuard/EsoCheck clinical utility studies, including a large registry.

Research and development for expanded test indications

Beyond the current indication, R&D efforts are geared toward broadening the market opportunity. An announcement on April 24, 2025, confirmed that a study supports an expanded indication and market opportunity for EsoGuard esophageal precancer testing.

Operating and scaling the clinical laboratory for test processing

The company operates a single, CLIA-certified clinical laboratory facility in Lake Forest, CA. The current expected annual capacity for this facility, without purchasing additional equipment specific to the test, is approximately 50,000 tests per year. You'll note the test volume in 2Q24 reached a single-quarter record of 4,042 tests, showing the existing infrastructure can handle significant spikes, though the company is in the process of scaling its operational capacity.

The current test center network includes locations across 11 metropolitan areas in the U.S. as of early 2024.

Lucid Diagnostics Inc. (LUCD) - Canvas Business Model: Key Resources

You're looking at the core assets Lucid Diagnostics Inc. (LUCD) relies on to execute its cancer prevention strategy. These aren't just abstract concepts; they are tangible, measurable items that underpin their valuation and near-term potential. Let's break down what they actually hold right now.

The foundation is definitely the proprietary technology suite. This includes the EsoGuard® Esophageal DNA Test, which is the lab-based assay, and the EsoCheck® Esophageal Cell Collection Device, which is the physical tool used in the office procedure. The test itself uses next-generation sequencing (NGS) to look at DNA methylation patterns.

Regarding the intellectual property portfolio, it's anchored by specific scientific findings. For instance, Lucid Diagnostics received a Notice of Allowance from the USPTO for a patent covering the proprietary method using methylation of the cyclin-A1 (CCNA1) gene to help detect esophageal precancer and cancer, which is a key component of the EsoGuard assay. The EsoGuard assay assesses DNA methylation at 31 sites on two genes, vimentin (VIM) and cyclin-A1 (CCNA1). This patent activity strengthens the portfolio underlying their groundbreaking technologies.

Financially, the balance sheet looks significantly better following recent capital raises. Lucid Diagnostics had cash and cash equivalents of $47.3 million as of September 30, 2025. That's a solid increase from the $22.4 million they held at the end of 2024. This cash position, bolstered by approximately $27.0 million in net proceeds from a public offering during the third quarter, extends their operational runway through 2026.

Here's a quick look at the operational metrics tied to the core product as of the end of Q3 2025:

Key Metric	Value/Amount	Date/Period
Cash and Cash Equivalents	$47.3 million	September 30, 2025
EsoGuard® Tests Processed	2,841	3Q25
EsoGuard Related Revenue Recognized	$1.2 million	3Q25
Net Proceeds from Q3 2025 Public Offering	Approximately $27.0 million	3Q25

The specialized market access and government affairs team is a critical non-financial resource, especially given the focus on reimbursement. A major recent win was the MolDX-participating Contractor Advisory Committee (CAC) meeting on September 4, 2025, where medical experts unanimously supported Medicare coverage for EsoGuard. This team is driving the final stages of the Local Coverage Determination (LCD) reconsideration process.

Also supporting the company's scientific and market penetration efforts are external collaborations and funding:

• Secured an $8 million National Institutes of Health (NIH) R01 grant to conduct a five-year clinical study evaluating EsoGuard in at-risk individuals without GERD symptoms.
• The technology behind EsoGuard and EsoCheck originated from research conducted at Case Western Reserve University (CWRU).
• The company is focused on expanding revenue streams through cash-pay programs and securing coverage with regional commercial insurers.

Honestly, the cash position and the unanimous expert support for Medicare coverage are the two biggest levers right now. Finance: draft 13-week cash view by Friday.

Lucid Diagnostics Inc. (LUCD) - Canvas Business Model: Value Propositions

You're looking at the core value Lucid Diagnostics Inc. (LUCD) offers to the healthcare ecosystem, which centers on shifting the paradigm for esophageal cancer prevention. The primary value is delivering non-invasive, office-based screening for esophageal precancer using the EsoGuard Esophageal DNA Test, which is performed via their EsoCheck Esophageal Cell Collection Device in a procedure taking less than three minutes in a clinical setting.

The proposition is built around the early detection of precancerous conditions like Barrett's Esophagus (BE). This is critical because esophageal cancer is highly lethal, and early detection is key to prevention. For instance, an NCI-sponsored study demonstrated a BE prevalence of 8.4% in at-risk patients who did not even present with symptoms of chronic heartburn (GERD). The company is focused on the millions of patients dealing with gastroesophageal reflux disease (GERD) who are at risk.

This diagnostic approach serves as a safe, simple alternative to costly, invasive upper endoscopy. Endoscopy is the traditional method, and the associated costs are significant, especially when considering surveillance protocols. Here's a quick comparison based on published economic evaluations:

Screening/Surveillance Strategy	Associated Cost Metric	Reported Amount (USD)
2-Yearly Surveillance (Endoscopy)	Total Costs	$5,309
At-Need Endoscopy	Total Costs	$3,182
Sedated Upper Endoscopy (sEGD)	Estimated Cost Range	$346-$506

The market analysis suggests that emerging non-endoscopic approaches, like the one Lucid Diagnostics Inc. offers, demonstrate superior cost-effectiveness versus standard endoscopy. Still, the commercial reality for Lucid Diagnostics Inc. shows they are scaling up, processing 2,841 EsoGuard tests in the third quarter of 2025, generating revenue of $1.2 million for that quarter. Full-year 2025 revenue is forecasted to be between $49.5 million and $51.5 million.

A cornerstone of the value proposition is the test's ability to rule out disease, which is quantified by its high negative predictive value (NPV). This is where the clinical data really shines:

• Published data shows an NPV of approximately 99% for detecting esophageal precancer, including short segment disease.
• The NCI-sponsored study in asymptomatic patients reported an excellent NPV of 100% for detecting esophageal precancer.

This high NPV means that if the test comes back negative, you can be highly confident the patient does not have the precancerous condition, which is a powerful statement for triaging the millions of at-risk individuals.

Lucid Diagnostics Inc. (LUCD) - Canvas Business Model: Customer Relationships

You're looking at how Lucid Diagnostics Inc. (LUCD) connects with the doctors and institutions that will actually use EsoCheck and EsoGuard. It isn't just about selling a test; it's about embedding a new cancer prevention step into established medical routines. Honestly, the customer relationship strategy hinges on proving value quickly to busy clinicians and securing larger, more stable contracts.

The commercial execution in 2025 shows they are pushing hard on multiple fronts. For instance, after recognizing $\text{\$0.8 million}$ in revenue in Q1 2025, they hit $\text{\$1.2 million}$ in both Q2 2025 and Q3 2025. That consistency, processing $\text{2,841}$ tests in the third quarter alone, suggests their sales and support structure is starting to stick with users.

Direct Sales Force Engagement with Physician Practices

Lucid Diagnostics Inc. has historically relied on a hybrid sales model. While they have utilized approximately $\text{fifty}$ independent sales representatives in the past, the focus in 2025 has shifted toward scaling a full-time commercial team nationwide, especially as they expand beyond just gastroenterology (GI) physicians to target primary care physicians (PCPs) who manage the vast majority of at-risk GERD patients. You see this focus on scaling market access infrastructure with the appointment of a new Senior Vice President, Market Access & Government Affairs, in Q3 2025.

Here's a look at the recent commercial output:

Metric	Q1 2025	Q2 2025	Q3 2025
EsoGuard Revenue	$\text{\$0.8 million}$	$\text{\$1.2 million}$	$\text{\$1.2 million}$
EsoGuard Tests Processed	Not specified	$\text{4,007}$ (Implied from Sales & Marketing table data)	$\text{2,841}$

High-Touch Support for Integrating EsoCheck into Clinical Workflow

For a new procedure, support has to be top-notch, or adoption stalls. The product itself is designed for ease of use, which helps the relationship. The EsoCheck procedure is performed in an office or health fair setting in less than $\text{three minutes}$. Furthermore, published data shows the test has an unprecedented negative predictive value (NPV) of approximately $\text{99\%}$ for detecting esophageal precancer, including short segment disease. That high performance, combined with a pristine safety record, makes the physician's job easier, reducing the need for constant troubleshooting.

• Procedure time: Less than $\text{three minutes}$.
• Clinical confidence: Approximately $\text{99\%}$ Negative Predictive Value (NPV).
• Support expansion: Building a network of Lucid Test Centers where Lucid-employed clinical personnel perform the procedure.

Contractual Relationships with Health Systems and Employers

This is where the long-term, stable revenue comes from. Lucid Diagnostics Inc. is actively driving toward contractually-guaranteed revenue streams, moving beyond the initial fee-for-service model. You saw them partner with a major health system in Q1 2025 to launch a comprehensive testing program across their digestive health and primary care networks. They also executed their first concierge medicine contract with LEAA Health in February 2025, focusing on cash-pay services. The company ended Q3 2025 with over $\text{\$47 million}$ in proforma cash, which was significantly bolstered by netting approximately $\text{\$27.0 million}$ from a public offering in that quarter, extending their runway through 2026 to support these contract escalations.

Educational Outreach to At-Risk Patient Populations (e.g., Firefighter Summit)

Targeted outreach is key for a screening tool. Firefighters are a prime example of a high-risk group they engage directly. Data shows that firefighters can have a $\text{62\%}$ higher risk of esophageal cancer due to toxic material exposure. Lucid Diagnostics Inc. has actively participated in screening events, such as those involving Chesapeake firefighters, where at least $\text{75}$ members were screened in one initiative. This type of direct engagement educates the community and builds a strong case for broader payer coverage, especially given the unanimous expert consensus supporting Medicare coverage for EsoGuard from the MolDx CAC meeting in September 2025.

The Medicare LDT payment determination remains a benchmark, set at $\text{\$1,938.01}$ effective January 1, 2021, which anchors the value proposition for these larger payor discussions.

Lucid Diagnostics Inc. (LUCD) - Canvas Business Model: Channels

You're looking at how Lucid Diagnostics Inc. gets its EsoGuard test into the hands of at-risk patients and how they process the samples. It's a multi-pronged approach, moving from traditional insurance reliance toward more immediate, contractually-guaranteed revenue streams as of late 2025.

The core of the channel strategy revolves around translating test volume into revenue through three key drivers mentioned by the Chairman and CEO: traditional claims submissions, direct contracting with employers and self-insured entities, and the cash-pay program focused on concierge medicine practices. The company ended the third quarter of 2025 with a total of 2,841 EsoGuard tests processed, generating approximately $1.2 million in revenue for that quarter.

Here is a quick look at the recent quarterly test volume and revenue performance:

Metric	Q1 2025	Q2 2025	Q3 2025
EsoGuard Tests Processed	3,034	2,756	2,841
EsoGuard Revenue	$0.8 million	$1.2 million	$1.2 million

The last twelve months revenue, as of September 30, 2025, totaled $4.40 million.

Direct sales team targeting gastroenterologists and PCPs

While the direct sales team's specific size isn't public, the strategy for engaging physicians is clear, especially concerning Medicare. The current Medicare mix is around 10-15% of total tests as of Q2 2025. Post-Medicare coverage, the goal is to reach approximately 40% of volume through targeted geographies and direct engagement with Primary Care Physicians (PCPs). Furthermore, the company is actively pursuing commercial coverage, reporting a pipeline of active conversations with commercial payers in the order of dozens, following the issuance of its first positive policy from Highmark New York in the second quarter.

Lucid's CLIA-certified laboratory for processing EsoGuard tests

All samples are sent to LucidDx Labs, which is CLIA-certified, CAP-accredited, and NYS CLEP approved. The lab infrastructure is built for scale; management indicated that capacity is approximately 5x the current volume, meaning no significant capital expenditure is required to ramp up testing. The cost structure is favorable for volume growth, with fixed lab costs around $1.2 million per quarter, and the next patient processed drives a 90% contribution margin.

Contracted cash-pay concierge medicine networks

This channel is a stated focus for contractually-guaranteed revenue, particularly in the second half of 2025. The company executed over 20 cash-pay concierge medicine contracts in the first few weeks following the launch of new sales channels targeting this revenue stream in early 2025. This focus is supported by partnerships, such as the one with Hoag, a regional healthcare network, to launch a system-wide program that includes their concierge medicine arm.

Direct-to-employer sales channel for corporate wellness programs

Direct contracting with self-insured employers is another key revenue driver. The company has dedicated executive leadership for this area, with a Vice President of Employer Markets. The strategy here is to secure direct contracts, which are critical for translating test volume growth into revenue, independent of the slower traditional claims or Medicare reimbursement timelines.

Finance: review Q3 2025 fixed lab cost variance against budget by next Tuesday.

Lucid Diagnostics Inc. (LUCD) - Canvas Business Model: Customer Segments

You're hiring before product-market fit, so every customer segment needs to be clearly defined by the value you bring them, especially when the product is a novel diagnostic like EsoGuard Esophageal DNA Test.

The core patient segment Lucid Diagnostics Inc. targets is patients with chronic gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. This focus is supported by clinical data showing that in at-risk patients meeting American Gastroenterological Association (AGA) guidelines for Barrett's Esophagus (BE) screening, the BE prevalence was found to be 8.4% in a study of asymptomatic patients. Furthermore, the EsoGuard test demonstrated an excellent negative predictive value (NPV) of 100% for detecting esophageal precancer in that study population. The company is also expanding its reach to at-risk patients without GERD symptoms. In the third quarter of 2025, Lucid Diagnostics Inc. processed 2,841 EsoGuard Esophageal DNA Tests.

The next set of customers are the ordering clinicians: Primary Care Physicians (PCPs) and Internal Medicine specialists, alongside Gastroenterology (GI) practices and digestive health centers. These providers are crucial because the EsoCheck Esophageal Cell Collection Device allows for a brief, noninvasive office procedure. One study showed an outstanding patient compliance rate of 85% for referral to confirmatory upper endoscopy following EsoGuard testing, suggesting ease of integration into clinical workflows. The company has also established specific partnerships, such as with Hoag, to expand testing access across its healthcare network.

The final segment involves the payers and large organizations that influence access and reimbursement, which includes self-insured employers and large health systems. Commercial success here hinges on securing coverage decisions. Lucid Diagnostics Inc. initiated patient testing and billing under its first positive commercial insurance coverage policy from Highmark Blue Cross Blue Shield. Critically, in September 2025, the MolDX Contractor Advisory Committee (CAC) meeting resulted in medical experts unanimously supporting Medicare coverage for EsoGuard, representing a key step toward securing this transformative reimbursement milestone.

Here's a quick look at the operational scale as of the end of the third quarter of 2025, which reflects the current commercial activity across these segments:

Metric	Value (Q3 2025)
EsoGuard Revenue	$1.2 million
EsoGuard Tests Processed	2,841
Proforma Cash Position	Over $47 million
GAAP Net Loss	Approximately $10.4 million
Market Capitalization	$145.9M

The expansion of the target population is supported by external funding, including an ongoing five-year multicenter clinical study supported by an $8 million National Institutes of Health (NIH) R01 grant.

The key access points for the test involve:

• Securing positive Medicare Local Coverage Determination (LCD) status.
• Translating commercial execution into contractually guaranteed revenue.
• Targeting the millions of patients with chronic GERD.
• Leveraging non-invasive, in-office sample collection.

Finance: draft 13-week cash view by Friday.

Lucid Diagnostics Inc. (LUCD) - Canvas Business Model: Cost Structure

You're looking at the expense side of the ledger for Lucid Diagnostics Inc. (LUCD) as of late 2025, and the story is one of significant investment to drive commercialization and secure future revenue streams, primarily through reimbursement.

The high operating expenses are the most immediate feature here. For the third quarter of 2025 (3Q25), total operating expenses clocked in at approximately $13.0 million, which is the rounded figure for the reported $12,970 thousand. This burn rate is what the company is spending to scale its commercial efforts and advance its clinical and regulatory standing.

The cost structure is heavily weighted toward supporting the business infrastructure and future growth, as you can see in the breakdown of the major categories. Here's a quick look at the components based on the reported figures for the three months ended September 30, 2025:

Cost Component (3Q25)	Amount (in thousands USD)
Total Operating Expenses	12,970
Net Sales, General, and Administrative (SG&A)	4,685
Net Research and Development (R&D)	1,149
Stock-Based Compensation Expense (Total)	1,272

Significant investment in Sales, General, and Administrative (SG&A) reflects the build-out of the commercial team and market access infrastructure. For 3Q25, the net general and administrative expenses were $4,685 thousand. This spend is critical right now, especially given the recent appointment of a new Senior Vice President, Market Access & Government Affairs, to lead rapidly expanding reimbursement activities. That team's work is a direct cost driver aimed at unlocking future revenue.

Research and development (R&D) for clinical trials and product enhancement remains a core, though smaller, component of the operating spend. Net R&D for the quarter was $1,149 thousand. This funding supports ongoing studies, such as those with the NIH and VA, which are crucial for expanding the target population and supporting reimbursement efforts.

Costs associated with laboratory operations and test processing are embedded within the total operating expenses, though not explicitly broken out as a standalone line item in the summary data. The company processed 2,841 EsoGuard® Esophageal DNA Tests in 3Q25. The variable costs tied to processing these tests, including reagents, labor, and lab overhead, are a direct function of this volume.

Finally, legal and regulatory costs for reimbursement efforts are a major focus area, evidenced by the strategic push for Medicare coverage. While a specific dollar amount for these legal and regulatory activities isn't isolated in the top-line summary, the progress-like the unanimous expert support at the MolDX Contractor Advisory Committee meeting on September 4, 2025-shows that significant resources are being deployed in this area to secure the Local Coverage Determination (LCD).

You should note the following key cost drivers:

• Net SG&A for 3Q25 was $4,685 thousand.
• Net R&D for 3Q25 was $1,149 thousand.
• Stock-based compensation expense was $1,272 thousand for the quarter.
• The company ended 3Q25 with over $47 million in proforma cash, extending runway through 2026.

Finance: draft 13-week cash view by Friday.

Lucid Diagnostics Inc. (LUCD) - Canvas Business Model: Revenue Streams

You're looking at how Lucid Diagnostics Inc. is turning its diagnostic pipeline into actual dollars as of late 2025. The revenue picture right now is heavily weighted toward initial commercial adoption while aggressively pursuing the transformative Medicare coverage milestone.

EsoGuard related test revenue for the third quarter of 2025 hit $1.2 million. Honestly, this number reflects the current revenue recognition policy under ASC 606, where revenue is recognized upon cash collection, which can lag behind the actual volume of tests processed. For context, in 3Q25, Lucid Diagnostics Inc. billed for about $7.1 million in pro forma revenue based on the 2,841 tests processed that quarter, meaning only about 17% was recognized as revenue.

Reimbursement payments from commercial insurance payors are a growing piece of the puzzle. You should note that the company initiated patient testing and billing under its first positive commercial coverage policy from Highmark Blue Cross Blue Shield, which became effective on May 26, 2025. Furthermore, management is actively pursuing direct contracting discussions with major payors, bolstered by a recent UnitedHealthcare guideline update that explicitly ties a positive EsoGuard result to appropriate follow-up endoscopy.

Cash-pay revenue from concierge medicine and employer contracts remains a focus area for immediate cash flow generation. Back in Q1 2025, Lucid Diagnostics Inc. highlighted strong progress in expanding these contracted programs targeting self-insured employers and concierge medicine practices. This direct-to-consumer or direct-to-employer channel helps bridge the gap while waiting for broader insurance adjudication.

Here's a quick look at the key operational and financial metrics underpinning these revenue streams as of the end of 3Q25:

Metric	Value (3Q25)	Context/Source
Recognized Revenue	$1.2 million	EsoGuard related revenue for 3Q25
Tests Processed (Volume)	2,841 tests	EsoGuard Esophageal DNA Tests in 3Q25
Pro Forma Billed Revenue	~$7.1 million	Billed amount for 3Q25 tests
Average Allowed (Commercial)	~$1,600 per test	Average allowed amount from adjudicated claims
Proforma Cash Position	$47.3 million	Cash and cash equivalents as of September 30, 2025

The potential future Medicare reimbursement is the primary catalyst for accelerating revenue recognition. The MolDX Contractor Advisory Committee meeting on September 4, 2025, resulted in medical experts unanimously supporting Medicare coverage for EsoGuard. Management anticipates a draft Local Coverage Determination (LCD) soon, likely by year-end, which would set up a final LCD in early 2026. Once finalized, this is expected to allow for a one-year look-back claim payment. The estimated reimbursement rate you are tracking for this future Medicare coverage is $1,938 per test.

Lucid Diagnostics Inc. is focusing its market access team on several key areas to maximize collections:

• Securing broader commercial insurance coverage beyond Highmark.
• Driving engagement with Medicare patients ahead of the final LCD.
• Converting event-based, contraction-guaranteed revenue opportunities.
• Improving payer processing metrics, such as rising adjudication rates (76%).

Finance: review the sensitivity of the $1,938 Medicare estimate against the current commercial average allowed of ~$1,600 for DCF modeling by next Tuesday.